Literature DB >> 24839147

Optimization of vancomycin dosing in very low-birth-weight preterm neonates.

Theresa Madigan1, Christine B Teng2, Jena Koshaish3, Kent R Johnson4, Kevin K Graner4, Ritu Banerjee2.   

Abstract

OBJECTIVE: To compare vancomycin serum trough concentrations and 24-hour area under the serum concentration-versus-time curve (AUC24) among very low-birth-weight (VLBW) premature infants before and after implementation of an institution-wide increase in neonatal vancomycin dosing. STUDY
DESIGN: We performed a retrospective analysis of vancomycin concentrations among preterm VLBW neonates before (2007-2010) and after (2010-2013) implementation of a new vancomycin dosing protocol consisting of increased vancomycin daily dose and frequency of administration.
RESULTS: Neonates weighing < 1,500 g and receiving the new vancomycin dosing regimen had lower rates of undetectable trough concentrations (24 vs. 50%, p = 0.04), higher median trough concentrations (10.8 vs. 5.9 µg/mL, p = 0.003), a higher proportion of goal trough concentrations of 10 to 20 µg/mL (35 vs. 4%, p = 0.005), and a significantly higher vancomycin AUC24 (438 vs. 320 mg·h/L, p = 0.004) compared with historical controls.
CONCLUSION: Increasing the vancomycin daily dose and dosing frequency led to an increase in vancomycin trough concentrations and AUC24, and a decrease in the proportion of undetectable (< 5.0 µg/mL) troughs, without an increase in toxicity among VLBW premature neonates. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839147      PMCID: PMC4418186          DOI: 10.1055/s-0034-1376183

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  15 in total

1.  Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.

Authors:  Adam Frymoyer; B Joseph Guglielmo; Adam L Hersh
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

2.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

3.  The influences of renal function and maturation on vancomycin elimination in newborns and infants.

Authors:  E V Capparelli; J R Lane; G L Romanowski; E J McFeely; W Murray; P Sousa; C Kildoo; J D Connor
Journal:  J Clin Pharmacol       Date:  2001-09       Impact factor: 3.126

4.  Pharmacokinetics and dose requirements of vancomycin in neonates.

Authors:  C Grimsley; A H Thomson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

5.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.

Authors:  Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

6.  Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.

Authors:  O Plan; G Cambonie; E Barbotte; P Meyer; C Devine; C Milesi; O Pidoux; M Badr; J C Picaud
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-05-01       Impact factor: 5.747

Review 7.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  The kinetic profile of vancomycin in neonates.

Authors:  R Silva; E Reis; M A Bispo; A M Almeida; I M Costa; F Falcão; J M Palminha; A C Falcão
Journal:  J Pharm Pharmacol       Date:  1998-11       Impact factor: 3.765

Review 9.  Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; William A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Pharmacotherapy       Date:  2009-11       Impact factor: 4.705

10.  Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.

Authors:  Matthijs de Hoog; Bert A van Zanten; Wim C Hop; Ellen Overbosch; Nynke Weisglas-Kuperus; John N van den Anker
Journal:  J Pediatr       Date:  2003-01       Impact factor: 4.406

View more
  4 in total

1.  Role of fluid status markers as risk factors for suboptimal vancomycin concentration during continuous infusion in neonates: an observational study.

Authors:  V L Cousin; Q Laudouar; N Le Saché; M Mokhtari; P Durand; V Furlan; P Tissières
Journal:  Eur J Pediatr       Date:  2022-05-17       Impact factor: 3.860

2.  Optimizing the Use of Antibacterial Agents in the Neonatal Period.

Authors:  Joseph B Cantey
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 3.  Adverse consequences of neonatal antibiotic exposure.

Authors:  Charles M Cotten
Journal:  Curr Opin Pediatr       Date:  2016-04       Impact factor: 2.856

Review 4.  Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review.

Authors:  Marta Mejías-Trueba; Marta Alonso-Moreno; Laura Herrera-Hidalgo; Maria Victoria Gil-Navarro
Journal:  Antibiotics (Basel)       Date:  2021-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.